MedTrace Logo

Cutaneous JAK in Vitiligo and Acne Vulgaris.

NCT03185312 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2017-06-14

No results posted yet for this study

Summary

The Janus kinase/signal transducer and activator of transcription (JAK-STAT) cytokine signaling pathway is an emerging area of interest in dermatology, and emerging evidence suggests that this pathway may play a crucial role in pathogenesis of inflammatory skin disorders.

Recent advances on the role of cytokines in the pathophysiology of immune mediated inflammatory diseases lead to the understanding that many pro inflammatory interleukins use JAK/STAT components for signal transduction .

Conditions

  • Vitiligo and Acne Vulgaris

Interventions

DIAGNOSTIC_TEST

skin biopsy

Clinical evaluation including full history taking and dermatological examination will be done for all patients. Assessment of disease severity will be performed using VASI score for vitiligo and Global acne severity grading for acne vulgaris Skin biopsies will be taken from lesional and non-lesional skin of patients as well as controls. immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3. Additionally, biopsies will be preserved in RNA later solution at -20°C. RNA isolation and real-time qPCR analysis will be performed for measurement of cutaneous JAK1, JAK2 and JAK3 gene expression.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Amira Abdel Motaleb, MD · Assiut University

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-31
Primary Completion
2019-01-31
Completion
2019-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03185312 on ClinicalTrials.gov